Health and economic burden associated with 15-valent pneumococcal conjugate vaccine serotypes in Korea and Hong Kong

Health and economic burden associated with 15-valent pneumococcal conjugate vaccine serotypes in Korea and Hong Kong

Use of pneumococcal conjugate vaccines (PCVs) has greatly reduced the incidence of invasive pneumococcal disease (IPD). V114 (VAXNEUVANCE™, Merck Sharp & Dohme Corp. a subsidiary of Merck & Co. Inc. Kenilworth, NJ, USA) is a 15-valent PCV currently approved in adults in the United States, co...

Full description

Bibliographic Details
Main Authors: Salini Mohanty, Tianyan Hu, GyongSeon Yang, Tsz K Khan, Kwame Owusu-Edusei, Isaya Sukarom
Format: Article
Language:English
Published: Taylor & Francis Group 2022-11-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
pneumococcal infections
vaccines, conjugate
asia
streptococcus pneumoniae
cost of illness
Online Access:http://dx.doi.org/10.1080/21645515.2022.2046433

Internet

http://dx.doi.org/10.1080/21645515.2022.2046433

Similar Items